Furosemide Exposure and Prevention of Bronchopulmonary Dysplasia in Premature Infants.
Birth Weight
Bronchopulmonary Dysplasia
/ prevention & control
Drug Administration Schedule
Female
Furosemide
/ administration & dosage
Gestational Age
Humans
Infant, Newborn
Infant, Premature
Infant, Premature, Diseases
/ prevention & control
Infant, Very Low Birth Weight
Male
Multivariate Analysis
Retrospective Studies
Sodium Potassium Chloride Symporter Inhibitors
/ administration & dosage
Treatment Outcome
BPD
chronic lung disease
diuretic
neonate
preterm
Journal
The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
27
07
2018
revised:
31
10
2018
accepted:
26
11
2018
pubmed:
24
12
2018
medline:
22
4
2020
entrez:
24
12
2018
Statut:
ppublish
Résumé
To evaluate the association between furosemide exposure and risk of bronchopulmonary dysplasia (BPD). This retrospective cohort study included infants (2004-2015) born at 23-29 weeks gestational age and 501-1249 g birth weight. We compared the demographic and clinical characteristics of infants exposed and not exposed to furosemide between postnatal day 7 and 36 weeks postmenstrual age. We examined the association between furosemide exposure and 2 outcomes: BPD and BPD or death. We performed multivariable probit regression models that included demographic and clinical variables in addition to 2 instrumental variables: furosemide exposure by discharge year, and furosemide exposure by site. Of 37 693 included infants, 19 235 (51%) were exposed to furosemide; these infants were more premature and had higher respiratory support. Of 33 760 infants who survived to BPD evaluation, 15 954 (47%) had BPD. An increase in the proportion of furosemide exposure days by 10 percentage points was associated with a decrease in both the incidence of BPD (4.6 percentage points; P = .001), and BPD or death (3.7 percentage points; P = .01). More days of furosemide exposure between postnatal day 7 and 36 weeks was associated with decreased risk of BPD and a combined outcome of BPD or death.
Identifiants
pubmed: 30579586
pii: S0022-3476(18)31690-1
doi: 10.1016/j.jpeds.2018.11.043
pmc: PMC6486845
mid: NIHMS1517211
pii:
doi:
Substances chimiques
Sodium Potassium Chloride Symporter Inhibitors
0
Furosemide
7LXU5N7ZO5
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
134-140.e2Subventions
Organisme : NICHD NIH HHS
ID : HHSN275201000003I
Pays : United States
Organisme : NICHD NIH HHS
ID : R21 HD080606
Pays : United States
Organisme : NIAAA NIH HHS
ID : HHSN275201000003C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201500006C
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD076676
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201300017C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201300017I
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
Pediatrics. 2000 Jun;105(6):1216-26
pubmed: 10835060
Arch Dis Child Fetal Neonatal Ed. 2000 Jul;83(1):F1-6
pubmed: 10873161
Am J Ther. 2002 Jul-Aug;9(4):317-28
pubmed: 12115021
Semin Neonatol. 2003 Feb;8(1):63-71
pubmed: 12667831
Pediatrics. 2004 Jun;113(6):1619-27
pubmed: 15173482
J Pediatr. 2004 Oct;145(4):503-7
pubmed: 15480375
Am Rev Respir Dis. 1992 May;145(5):990-8
pubmed: 1586077
Pediatrics. 2006 Feb;117(2):357-66
pubmed: 16452354
Epidemiology. 2006 May;17(3):260-7
pubmed: 16617274
JAMA. 2007 Jan 17;297(3):278-85
pubmed: 17227979
Clin Pharmacol Ther. 2007 Sep;82(3):300-9
pubmed: 17460608
Pediatrics. 2010 Feb;125(2):e214-24
pubmed: 20100760
Clin Perinatol. 2010 Mar;37(1):49-70
pubmed: 20363447
Am J Respir Crit Care Med. 2011 Jun 15;183(12):1715-22
pubmed: 21471086
Cochrane Database Syst Rev. 2011 Sep 07;(9):CD001453
pubmed: 21901676
J Pediatr. 1990 Jul;117(1 Pt 1):112-8
pubmed: 2196353
Chest. 2012 Jun;141(6):1554-1567
pubmed: 22116801
Early Hum Dev. 2012 Jul;88(7):509-15
pubmed: 22236557
Pediatrics. 2012 Aug;130(2):270-8
pubmed: 22778301
JAMA. 2013 Jan 16;309(3):241-2
pubmed: 23321761
Pediatrics. 2013 Apr;131(4):716-23
pubmed: 23478874
J Pediatr. 2013 Oct;163(4):955-60.e1
pubmed: 23769501
Stat Med. 2014 Jun 15;33(13):2297-340
pubmed: 24599889
Am J Perinatol. 2015 Jan;32(1):49-56
pubmed: 24801161
Cochrane Database Syst Rev. 2014 May 13;(5):CD001146
pubmed: 24825456
Early Hum Dev. 2015 Jun;91(6):345-50
pubmed: 25933212
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753
JAMA Pediatr. 2015 Dec;169(12):e153785
pubmed: 26642118
Pharmacogenomics J. 2017 Mar;17(2):192-200
pubmed: 26927285
J Pediatr. 2016 Jun;173:39-44.e1
pubmed: 26944265
J Perinatol. 2016 Aug;36(8):581-5
pubmed: 27228508
Pediatr Cardiol. 2017 Jan;38(1):155-161
pubmed: 27826711
Acta Paediatr. 2017 Mar;106(3):366-374
pubmed: 27862302
Sci Rep. 2016 Nov 21;6:37154
pubmed: 27869205
J Pediatr. 2018 Jun;197:300-308
pubmed: 29551318
J Pediatr. 2018 Jun;197:42-47.e1
pubmed: 29599068
Clin Perinatol. 2018 Jun;45(2):273-291
pubmed: 29747888
J Pediatr. 2018 Nov;202:56-62.e2
pubmed: 30172431
N Engl J Med. 1973 May 24;288(21):1087-90
pubmed: 4697939
J Pediatr. 1984 Oct;105(4):603-9
pubmed: 6384452
Clin Pediatr (Phila). 1993 Jul;32(7):393-400
pubmed: 8365073